focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 250.00
Bid: 240.00
Ask: 260.00
Change: 0.00 (0.00%)
Spread: 20.00 (8.333%)
Open: 250.00
High: 250.00
Low: 250.00
Prev. Close: 250.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

27 Jan 2023 17:45

RNS Number : 1644O
Faron Pharmaceuticals Oy
27 January 2023
 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Faron Pharmaceuticals Ltd

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii: (Increase of holding due to issuance of new shares)

X

3. Details of person subject to the notification obligation iv

Name

Varma Mutual Pension Insurance Company

City and country of registered office (if applicable)

Helsinki, Finland

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

27.01.2023

6. Date on which issuer notified (DD/MM/YYYY):

27.01.2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

4.16%

4.16%

2,641,503

Position of previous notification (if

applicable)

3.16%

3.16%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

FI4000153309

2,641,503

4.16%

SUBTOTAL 8. A

2,641,503

4.16%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Varma Mutual Pension Insurance Company

4.16%

4.16%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

Faron share issue per 27.01.2023

 

Place of completion

Helsinki, Finland

Date of completion

27.01.2023

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLMZGZMNNRGFZM
Date   Source Headline
26th Aug 20217:00 amRNSHalf-Year Financials, January 1 – June 30 2021
25th Aug 20217:00 amRNSFirst Patient Dosed in Phase II/III COVID-19 Trial
28th Jul 20217:00 amRNSNotice of Half-Year Report
12th Jul 20217:00 amRNSFaron to Host KOL Webinar on Clever-1 Receptor
22nd Jun 20217:00 amRNSUpdated corporate presentation
14th Jun 202111:05 amRNSSecond Price Monitoring Extn
14th Jun 202111:00 amRNSPrice Monitoring Extension
14th Jun 20217:00 amRNSBexmarilimab granted key US patent
3rd Jun 20217:00 amRNSBexmarilimab results published in CCR
17th May 20217:00 amRNSBexmarilimab shows promising anti-tumour activity
14th May 20217:00 amRNSUS rights to patent related to Traumakine
10th May 20212:30 pmRNSHolding(s) in Company
29th Apr 202112:45 pmRNSGrant of options
23rd Apr 20211:45 pmRNSBoard Change
23rd Apr 20211:45 pmRNSResult of AGM
29th Mar 20217:00 amRNSAppointment of a Broker
25th Mar 20217:45 amRNSExercise of Options
25th Mar 20217:30 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
25th Mar 20217:15 amRNSFaron´s Annual Report 2020 published
25th Mar 20217:00 amRNSFinancial statement January 1 to December 31 2020
22nd Mar 20217:00 amRNSBexmarilimab (Clevegen) development update
11th Mar 20217:00 amRNSFaron to Present at Oppenheimer Conference
2nd Mar 20217:00 amRNSFaron to Present at H.C. Wainwright Conference
25th Feb 20217:00 amRNSNotice of Full-Year Results and Annual Report
17th Feb 20214:30 pmRNSHolding(s) in Company
12th Feb 20213:00 pmRNSRegistration of Placing Shares
12th Feb 20217:00 amRNSResults of Placing and Issue Price
11th Feb 20214:30 pmRNSProposed Issue and Placing of Shares
26th Jan 20217:00 amRNSUpdate on TRAUMAKINE development
20th Jan 20212:06 pmRNSSecond Price Monitoring Extn
20th Jan 20212:01 pmRNSPrice Monitoring Extension
20th Jan 20217:00 amRNSBexmarilimab (Clevegen) development update
18th Jan 20212:05 pmRNSSecond Price Monitoring Extn
18th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Jan 202111:06 amRNSSecond Price Monitoring Extn
18th Jan 202111:01 amRNSPrice Monitoring Extension
18th Jan 20217:00 amRNSUS Department of Defense to support TRAUMAKINE
4th Jan 20217:00 amRNSFaron to Present at H.C. Wainwright
21st Dec 20207:00 amRNSFaron’s financial calendar for 2021
10th Dec 20207:00 amRNSPresents at ESMO Immuno-Oncology Virtual Congress
23rd Nov 20207:30 amRNSTo Participate in Upcoming Investor Conferences
23rd Nov 20207:00 amRNSBexmarilimab (Clevegen) development update
20th Nov 20207:00 amRNSIssue of Equity
16th Oct 202011:35 amRNSFirst Results from WHO Solidarity Trial
14th Oct 20202:15 pmRNSGrant of options
30th Sep 20209:45 amRNSHolding(s) in Company
24th Sep 20207:15 amRNSExercise of options
24th Sep 20207:00 amRNSHalf-year Report
18th Sep 20207:00 amRNSMATINS trial data presented at ESMO
9th Sep 202012:00 pmRNSFaron to Present at H.C. Wainwright Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.